New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 23, 2012
05:55 EDTCLDX, CLDXCelldex management to meet with Leerink
Meeting to be held in New York on November 30 hosted by Leerink.
News For CLDX From The Last 14 Days
Check below for free stories on CLDX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 16, 2014
14:02 EDTCLDXCelldex Phase 1 study of CDX-1401 demonstrates robust antibody response
Subscribe for More Information
April 15, 2014
08:19 EDTCLDXLeerink's pharma and biotech analysts hold an analyst/industry conference call
Subscribe for More Information
April 7, 2014
16:02 EDTCLDXCelldex says CDX-014 to enter clinical development
Celldex Therapeutics reported results of preclinical studies evaluating the anti-tumor activity of CDX-014 against a variety of cell lines. Based on the results, CDX-014 will enter clinical development. CDX-014 is an antibody drug conjugate that targets the protein TIM-1. "The data presented today confirm that CDX-014 effectively targets the tumor marker TIM-1 in vitro and elicits significant anti-tumor activity in key models. We are currently completing manufacturing and IND-enabling studies and anticipate that CDX-014 will enter Phase 1 clinical studies in renal cell carcinoma and potentially other TIM-1 expressing tumors in 2015," said Tibor Keler, senior VP and Chief Scientific Officer of Celldex.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use